Immunohistochemical analysis of the tumor regions revealed low intensity p85 and PCNA expression in p42-AV or two of p42-CTD-AV (183–394 and 280–394 aa) injection groups compared with control vector group (Fig. 7g), suggesting that p42 and its CTD inhibits breast cancer growth in vivo. This evidence concerns the gene PCNA and neoplasm.